Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan

Abstract Introduction Tumor necrosis factor inhibitors (TNFi) are commonly used as first-line therapy (biologic disease-modifying antirheumatic drug [bDMARD] and targeted synthetic DMARD [tsDMARD]: defined as targeted therapy) for patients with moderate-to-severe rheumatoid arthritis (RA), usually c...

Full description

Bibliographic Details
Main Authors: Emma Sullivan, Jim Kershaw, Stuart Blackburn, Puneet Mahajan, Susan H. Boklage
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-05-01
Series:Rheumatology and Therapy
Subjects:
Disease-modifying antirheumatic drugs
Physician
Rheumatoid arthritis
Switching
Tumor necrosis factor inhibitor
Online Access:https://doi.org/10.1007/s40744-020-00211-w

Internet

https://doi.org/10.1007/s40744-020-00211-w

Similar Items